



AscencioDx[®]
COVID-19 Test &
Molecular Detector




“Where Speed, Efficiency, and Accuracy Align”

FEATURE	BENEFIT
Cost Effectiveness	Superior functionality and performance at an affordable price.
Accuracy	Highly accurate test results, minimizing chances of errors and enhancing diagnostic confidence.
Easy & Convenient	The CLIA-waived AscencioDx system is incredibly user-friendly and does not require extensive training, making it a suitable choice for all healthcare settings.
Time to Result	Receive actionable test results in as little as 20 minutes.
Expandable Platform	Not just for COVID. Other respiratory and sexual health panels currently in development.

STAT TECHNOLOGIES

SIMPLE-TO-PERFORM TEST PROCEDURE



PRODUCT APPLICATIONS



AscencioDx TECHNICAL APPROACH

Test Target Technology

- RT-LAMP molecular analysis
- Real-time SARS-CoV-2 viral RNA detection via fluorescence signals
- Novel enzyme and probe design (patent pending)
- Redundancy: detects 3 distinct regions of the SARS-CoV-2 viral genome, robust against mutation
- RNA internal control in every test flags problems due to sample mishandling

CATALOG NUMBERS

Item	Catalog #
The AscencioDx Molecular Detector - Individual	1000-00ENUS
The AscencioDx Molecular Detector - Case (10 Detectors)	1002-00ENUS
The AscencioDx Molecular Detector - Master Pack (4 Cases)	1011-00ENUS
The AscencioDx COVID-19 Test - Master Pack (40 Tests)	1004-00ENUS
The AscencioDx COVID-19 Starter Kit - 1 Detector & 1 Test Master Pack	STARTER-KIT



Proudly Manufactured in the USA
to our strict quality standards.



STAT Technologies
Golden Valley, MN USA
www.stat-technologies.com
info@stat-technologies.com
PH: 800-217-7828

Note: This product has not been FDA cleared or approved, but has been authorized for emergency use by FDA under an EUA for use by authorized laboratories. This product has been authorized only for the detection of nucleic acid from SARS-CoV-2, not for any other viruses or pathogens. The emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or authorization is revoked sooner.

Lit. Re-order No: MKTG-07-STAT
2023-07-14-V3.1.0